Literature DB >> 10791510

Pharmacoeconomic analyses: making them transparent, making them credible.

D Rennie, H S Luft.   

Abstract

Mesh：

Year:  2000        PMID： 10791510     DOI： 10.1001/jama.283.16.2158

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  27 in total

Review 1.  Pharmacoeconomic fellowships: the need for outcome measures.

Authors:  V Maio; T K Girts; J H Lofland; D B Nash
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Ontario's formulary committee: how recommendations are made.

Authors:  Anne M PausJenssen; Peter A Singer; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Rethinking prescribing in the United States.

Authors:  Andrew Ellner
Journal:  BMJ       Date:  2003-12-13

4.  Integrity in scientific publishing.

Authors:  Drummond Rennie
Journal:  Health Serv Res       Date:  2010-03-10       Impact factor: 3.402

5.  Utilities and QALYs in health economic evaluations: glossary and introduction.

Authors:  Gianni Virgili; Daniela Koleva; Livio Garattini; Rita Banzi; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

6.  Reporting pharmacoeconomic evaluations.

Authors:  C I Carswell; J A Paladino
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  Pharmacoeconomic studies in Italy: a critical review of the literature.

Authors:  D Cornago; L Li Bassi; P De Compadri; L Garattini
Journal:  Eur J Health Econ       Date:  2006-12-21

Review 8.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

9.  Evaluating health care programs by combining cost with quality of life measures: a case study comparing capitation and fee for service.

Authors:  Richard Grieve; Jasjeet S Sekhon; Teh-Wei Hu; Joan R Bloom
Journal:  Health Serv Res       Date:  2008-03-17       Impact factor: 3.402

10.  ACE inhibitors: back to prime time?

Authors:  Milan Gupta; Subodh Verma; G B John Mancini
Journal:  Heart       Date:  2007-09       Impact factor: 5.994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.